Trial: 202008197

A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

Phase

III (Cancer Control)

Principal Investigator

Oh, Stephen

Disease Site

Myeloproliferative Disease; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov